Patient Square Capital’s Roivant Sciences ROIV Stock Holding History

Patient Square Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$284M	Sell	8,020,928 -145,119	-2%	-$4.29M	43.97%	1
2026 Q1	$226M	Hold	8,166,047	–	–	40.13%	1
2025 Q4	$177M	Sell	8,166,047 -4,313,953	-35%	-$85.1M	37.93%	1
2025 Q3	$189M	Hold	12,480,000	–	–	50.51%	1
2025 Q2	$141M	Hold	12,480,000	–	–	50.71%	1
2025 Q1	$126M	Hold	12,480,000	–	–	52.09%	1
2024 Q4	$148M	Buy	12,480,000 +251,535	+2%	+$2.97M	55.22%	1
2024 Q3	$141M	Hold	12,228,465	–	–	52.38%	1
2024 Q2	$129M	Hold	12,228,465	–	–	59.99%	1
2024 Q1	$129M	Sell	12,228,465 -411,455	-3%	-$4.44M	54.89%	1
2023 Q4	$142M	Hold	12,639,920	–	–	77.6%	1
2023 Q3	$148M	Hold	12,639,920	–	–	81.13%	1
2023 Q2	$127M	Buy	12,639,920 +5,813,953	+85%	+$52M	62.03%	1
2023 Q1	$50.4M	Hold	6,825,967	–	–	40.49%	2
2022 Q4	$54.5M	Buy	+6,825,967	New	+$38M	23.06%	2

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Patient Square Capital's ROIV Position: Q2 2026 in Review

Patient Square Capital reduced its Roivant Sciences (ROIV) stake by 1.8% in Q2 2026, selling an estimated $4.29M and leaving 8,020,928 shares worth $284M. The position accounts for 43.97% of the portfolio, ranked #1.

Patient Square Capital first reported a position in ROIV in Q4 2022 and has held it in 15 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Patient Square Capital held 8,020,928 shares of Roivant Sciences worth $284M as of Q2 2026.
Patient Square Capital sold 145,119 Roivant Sciences shares in Q2 2026, an estimated $4.29M.
Roivant Sciences made up 43.97% of Patient Square Capital's portfolio in Q2 2026, its #1 holding.
Patient Square Capital first reported a position in Roivant Sciences in Q4 2022 and has held it in 15 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.